ADDING INSULIN GLARGINE TO ORAL THERAPY IN PATIENTS WITH TYPE 2 DIABETES RESULTS IN LONGER PERSISTENCE WITH TREATMENT COMPARED TO NPH INSULIN

被引：1

作者：

Pfohl, M. ^{[1
]}

Dippel, F. W. ^{[2
]}

Kostev, K. ^{[3
]}

Kotowa, W. ^{[4
]}

机构：

[1] Evangel Bethesda Johanniter Klinikum GmbH, Duisburg, Germany

[2] Sanofi Aventis Germany GmbH, Berlin, Germany

[3] IMS HEALTH GmbH & Co, OHG, Frankfurt, Germany

[4] IMS HEALTH, Nurnberg, Germany

来源：

VALUE IN HEALTH | 2008年 / 11卷 / 06期

关键词：

D O I：

10.1016/S1098-3015(10)66691-0

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

引用

页码：A509 / A510

页数：2

共 50 条

[31] Treatment to target in Type 2 diabetes: successful glycaemic control with less nocturnal hypoglycaemia with insulin glargine versus NPH insulin added to oral therapy
Riddle, M
Rosenstock, J
[J]. DIABETOLOGIA, 2002, 45 : A52 - A52
[32] Lower incidence of nocturnal hypoglycaemia in patients with Type 2 diabetes treated with insulin glargine compared with NPH insulin, given as a combination regimen with oral agents.
Benedetti, MM
Hamburg, E
Dressler, A
Ziemen, M
[J]. DIABETOLOGIA, 2002, 45 : A259 - A259
[33] Reduced hypoglycemia risk with insulin glargine - A metaanalysis comparing insulin glargine with human NPH insulin in type 2 diabetes
Rosenstock, J
Dailey, G
Massi-Benedetti, M
Fritsche, A
Lin, ZN
Salzman, A
[J]. DIABETES CARE, 2005, 28 (04) : 950 - 955
[34] Insulin glargine is associated with less hypoglycaemia than NPH insulin in older patients with Type 2 diabetes
Riddle, M
Massi-Benedetti, M
Häring, HU
Dailey, G
Murray, F
Lin, Z
Rosenstock, J
[J]. DIABETOLOGIA, 2004, 47 : A328 - A328
[35] Improved glycemic control and reduced nocturnal hypoglycemia in patients with type 2 diabetes with morning administration of insulin glargine compared with NPH insulin
Fritsche, A
Schweitzer, MA
Haring, H
[J]. DIABETES, 2002, 51 : A54 - A54
[36] Co-administration of insulin glargine with oral therapy in patients with Type 2 diabetes allows flexible dosing and improved glycaemic control with reduced hypoglycaemia compared with NPH insulin.
Busch, K
Fritsche, A
Häring, HU
Schweitzer, MA
Vesper, I
[J]. DIABETOLOGIA, 2003, 46 : A6 - A6
[37] Improved glycaemic control and reduced nocturnal hypoglycaemia in patients with Type 2 diabetes with morning administration of insulin glargine compared with NPH insulin
Fritsche, A
Schweitzer, MA
Häring, H
[J]. DIABETOLOGIA, 2002, 45 : A52 - A52
[38] Treatment to target study: Timing and frequency of nocturnal hypoglycemia. The value of adding bedtime basal insulin glargine over NPH insulin in insulin-naive patients with Type 2 diabetes on oral agents
Rosenstock, J
Riddle, MC
[J]. DIABETES, 2002, 51 : A482 - A482
[39] Cost analysis of diabetes treatment with glargine insulin or NPH insulin in Spain
Rubio-Terrés, C
Rodriguez, J
Bolinder, B
[J]. VALUE IN HEALTH, 2003, 6 (03) : 336 - 336
[40] Insulin Glargine (GLAR) and NPH Insulin (NPH) in Real Life in Russia in Patients with Type 2 Diabetes (T2D)
Shestakova, Marina V.
Glinkina, Irina V.
[J]. DIABETES, 2009, 58 : A530 - A530

← 1 2 3 4 5 →